PharmaTher Holdings Ltd (XCNQ:PHRM) Stock News, Headlines & Updates
PharmaTher Holdings Ltd Stock News from GuruFocus
- 1
Jul 02, 2025
PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine | PHRRF Stock News
GuruFocus News • 7:21am
PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine
Marketwired • 7:00am
Jun 24, 2025
PharmaTher (PHRRF) Secures U.S. Patent for Ketamine ALS Treatment | PHRRF Stock News
GuruFocus News • 7:31am
PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market
Marketwired • 7:00am
Jun 18, 2025
PharmaTher (PHRRF) Embraces FDA's Priority Voucher Program for Ketamine Development | PHRRF Stock News
GuruFocus News • 7:33am
PharmaTher Applauds FDA's New Commissioner's National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and Nat
GuruFocus News • 7:20am
May 16, 2025
PharmaTher (PHRRF) Sees FDA Review Date for Ketamine Extended | PHRRF Stock News
GuruFocus News • 7:33am
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025 | PHRRF Stock News
GuruFocus News • 7:31am
PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025
Marketwired • 7:00am
May 14, 2025
PharmaTher (PHRRF) Introduces KetaVault to Enhance Ketamine Research | PHRRF Stock News
GuruFocus News • 8:05am
- 1
Show
Entries
Headlines
Total 0- 1
No recent news